Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for all patients with cancers caused by KRAS m
KRAS is the most mutated gene in cancer with mutations occurring in 17%-25% of all cancers, affecting millions of patients worldwide. It plays a crucial role in tumour growth, as it is important for … [+4298 chars]
